KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) EPS (Weighted Average and Diluted) (2016 - 2026)

Abbott Laboratories' EPS (Weighted Average and Diluted) history spans 18 years, with the latest figure at $0.61 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 19.74% to $0.61 in Q1 2026 year-over-year; TTM through Mar 2026 was $3.58, a 53.51% decrease, with the full-year FY2025 number at $3.72, down 51.31% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.61 in Q1 2026 for Abbott Laboratories, down from $1.02 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ABT hit a ceiling of $5.26 in Q4 2024 and a floor of $0.59 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $1.13 across 5 years, with a median of $0.82 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 478.02% in 2024 and later crashed 80.61% in 2025.
  • Tracing ABT's EPS (Weighted Average and Diluted) over 5 years: stood at $0.59 in 2022, then skyrocketed by 54.24% to $0.91 in 2023, then soared by 478.02% to $5.26 in 2024, then crashed by 80.61% to $1.02 in 2025, then plummeted by 40.2% to $0.61 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ABT at $0.61 in Q1 2026, $1.02 in Q4 2025, and $0.94 in Q3 2025.